Poster Presentations Session I
Poster Presentations Session I Monday, May 21, 2018
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:00 PM
POSTER AUTHOR DISCUSSION: 1:00 PM - 2:00 PM
POSTERS DISMANTLE: 2:00 PM


Poster display locations are shown below the poster codes
RESEARCH ON METHODS - Clinical Outcomes Methods
PRM1
A1
CONVERTING EORTC QLQ-C30 SCORES TO EQ-5D UTILITY SCORES IN THE BRIGATINIB ALTA STUDY
Kawata AK1, Lenderking WR1, Eseyin OR1, Kerstein D2, Huang J2, Huang H2, Lin HM2
1Evidera, Bethesda, MD, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

PRM2
A2
TRANSLATION, VALIDATION AND PSYCHOMETRIC EVALUATION OF PATIENT SATISFACTION WITH PHARMACIST SERVICES QUESTIONNAIRE: THE URDU VERSION
Hashmi FK1, Saleem F2, Hassali MA3, Iqbal Q2, ud Din Z2, Saeed H1
1University of the Punjab, Lahore, Pakistan, 2University of Balochistan, Baluchistan, Pakistan, 3Universiti Sains Malaysia, Pulau Penang, Malaysia

PRM3
A3
QUANTIFYING THE IMPACT OF RATER SEVERITY/LENIENCY ON CLINROS
Mallinson T1, Pape T2, Guernon A3, Weaver JA1, Herrold A2
1George Washington University, Washington, DC, USA, 2Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA, 3Marianjoy Rehabilitaton Hospital, Wheaton, IL, USA

PRM4
A4
CHALLENGES IN OUTLIER SURGEON ASSESSMENT IN THE ERA OF PUBLIC REPORTING
Mao J1, Girardi L1, Gaudino MF1, Sedrakyan A2
1Weill Cornell Medical College, New York, NY, USA, 2Weill Cornell Medicine, New York, NY, USA

PRM5
A5
DEVELOPING A CONSOLIDATED CHECKLIST (STRWE-RETRO) TO ASSESS THE REPORTING QUALITY OF REAL WORLD EVIDENCE STUDIES BASED ON RETROSPECTIVE DATA ANALYSES
Pandey R1, Baum E2, Ma H2, Pandey P1, Dhagale P1, Sawant A1, Shah V1, Gupta P3
1SIRO Clinpharm Pvt Ltd, Maharashtra, India, 2Janssen Global Services, Titusville, NJ, USA, 3All India Institute of Medical Sciences, Patna, India

PRM6
A6
DEFINING AND ESTIMATING THE CURE FRACTION BIAS IN SURVIVAL MODELLING OF NOVEL IMMUNO-ONCOLOGY THERAPY AGENTS IN SMALL-CELL LUNG CANCER
Gordon J1, McEwan P1, Ward T1, Penrod JR2, Wagner S2, Yuan Y2
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA

PRM7
A7
THE IMPACT OF RESPONSE AT A LANDMARK ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF THE VALUE OF IMMUNO-ONCOLOGY (I-O) TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)
Santi I1, Johal S1, Yuan Y2, Penrod JR2
1PAREXEL International, London, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA

PRM8
A8
ASSESSMENT OF ANTICHOLINERGIC BURDEN SCALES AND MEASURES FOR ESTIMATING ANTICHOLINERGIC EXPOSURE IN RETROSPECTIVE U.S. DATABASE ANALYSES
Lozano-Ortega G1, Ng DB2, Johnston KM1, Cheung A1, Guttschow A2, Gooch K3, Szabo SM1, Dmochowski R4, Campbell N5, Wagg A6
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2Astellas Scientific and Medical Affairs, Inc, Northbrook, IL, USA, 3Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 4Vanderbilt University Medical Center, Nashville, TN, USA, 5Purdue University, College of Pharmacy, Indianapolis, IN, USA, 6University of Alberta, Edmonton, AB, Canada

PRM9
A9
ASSOCIATION OF DISEASE MODIFYING ANTIRHEUMATIC DRUGS (DMARD) AND TUMOR NECROSIS FACTOR (TNF)- ALPHA INHIBITOR THERAPY AND INFECTION IN RHEUMATOID ARTHRITIS PATIENTS IN A MEDICAID POPULATION
Dibie C1, Rong Y2, Ramachandran S2, Banahan III B1, Noble S3
1Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 2University of Mississippi, University, MS, USA, 3Office of the Governor, Mississippi Division of Medicaid, Jackson, MS, USA

PRM10
A10
FIRST STEPS IN CHOOSING APPROPRIATE INSTRUMENTS/MEASUREMENTS FOR A CORE OUTCOME SET: AN EXAMPLE FROM COREHEM
Tunis SR1, Skinner MW2, Clearfield E1, Messner DA1, Al Naber J1, Iorio A3
1Center for Medical Technology Policy, Baltimore, MD, USA, 2Institute for Policy Advancement, Ltd., Washington, DC, USA, 3McMaster University, Hamilton, ON, Canada

PRM11
A11
THE USE OF REAL WORLD DATA TO DEFINE THE PREVALENCE, SEVERITY, AND ETIOLOGY OF MITRAL VALVE REGURGITATION
Cork D1, Gunnarsson C2, Kottenmeier E3, Mollenkopf S3, Verta P3, Mehta H1
1San Diego, San Diego, CA, USA, 2Gunnarsson Consulting, Jupiter, FL, USA, 3Edwards Lifesciences, Irvine, CA, USA

PRM12
A12
UNDERSTANDING SEPSIS RECOGNITION AND MANAGEMENT IN EMERGENCY ROOM SETTINGS TO IMPROVE PATIENT OUTCOMES
Fishbein E1, Brooks EA1, Piehl M2, Blaivas M3, Zambelli-Weiner A4
1Decision Driver Analytics, Inc., Asheville, NC, USA, 2410 Medical, Durham, NC, USA, 3University of South Carolina School of Medicine, Columbia, SC, USA, 4Translational Technologies International, Hampstead, MD, USA

PRM13
A13
CHALLENGES IN COMPARING REMISSION OUTCOMES IN NETWORK META-ANALYSES IN ULCERATIVE COLITIS
Nelson L1, Curry A2, Ralston S2
1SIRIUS Market Access, Newcastle upon Tyne, UK, 2SIRIUS Market Access, London, UK

PRM14
A14
SOME NOVEL METHODS FOR HETEROGENOUS TREATMENT EFFECT ESTIMATION WITH AN APPLICATION TO THE ASSOCIATION BETWEEN MEDICATION ADHERENCE AND RESOURCE UTILIZATION
McLaughlin SM
Anthem, Inc., Columbia, MD, USA

PRM15
A15
THE HORSE(SAS) NOW HAS A CART – COMPARING SAS TO SALFORD SYSTEM’S CATEGORIZATION AND REGRESSION TREE PROCEDURES
Mink DR, Smith BN, Pasta DJ
ICON Clinical Research, North Wales, PA, USA

PRM16
A16
MISSING VALUE IMPUTATION IN PRAGMATIC CLINICAL TRIALS (PCT): AN ACCURACY ANALYSIS
Wasser TE, Turner RM
HealthCore, Wilminton, DE, USA

PRM17
A17
ASSESSING TYPE AND IMPACT OF BIASES POTENTIALLY OCCURRING WHEN ANALYZING REAL WORLD EVIDENCE: THE CASE OF SECOND LINE TREATMENT FOR OVARIAN CANCER
Kuehne F1, Arvandi M2, Hess LM3, Faries DE3, Matteucci Gothe R2, Gothe H2, Beyrer J3, Zeimet AG4, Stojkov I2, Mühlberger N5, Oberaigner W2, Marth C4, Siebert U6
1Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 2Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, Hall i.T., Austria, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Medical University Innsbruck, Innsbruck, Austria, 5UMIT - University for Health Sciences, Medical Informatics and Technology / Institute of Public Health, Medical Decision Making and Health Technology Assessment, Hall i.T., Austria, 6UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health. Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA

PRM18
A18
DEVELOPING AN ALGORITHM TO IDENTIFY PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA IN AN ADMINISTRATIVE CLAIMS DATABASE
Agarwal S1, McManus A1, Querbes W1, Simon A1, Noxon V2, Cole A2, Johnson BH2
1Alnylam Pharmaceuticals, Cambridge, MA, USA, 2Truven Health Analytics, an IBM Company, Cambridge, MA, USA

PRM19
A19
MACHINE LEARNING TO DETECT AND DIAGNOSE ATRIAL FIBRILLATION AND ATRIAL FLUTTER (AF/F) USING ROUTINE CLINICAL DATA
Hill NR1, Ayoubkhani D2, Lumley M3, Lister S1, Farooqui U1, Clifton D4, O'Neil M5, McEwan P2, Gordon J2
1Bristol Myers Squibb, Uxbridge,, UK, 2Health Economics and Outcomes Research Ltd, Cardiff, UK, 3Pfizer, Tadworth, UK, 4Oxford University, Oxford, UK, 5Kings College London, London, UK

PRM20
A20
CHI-SQUARE AUTOMATIC INTERACTION DETECTION (CHAID) ANALYSIS: UNDERSTANDING AND INFORMING TREATMENT CHOICE OF SECOND-LINE METASTATIC UROTHELIAL CANCER THERAPY
Jaffe DH1, Kwan J2, Li VW3, Li S3, DeCongelio M3, Pomerantz D2, Hoover C3, Goulden S4, Gooden KM5
1Kantar Health, Tel Aviv, Israel, 2Kantar Health, Horsham, PA, USA, 3Kantar Health, New York, NY, USA, 4Bristol-Myers Squibb, Uxbridge, UK, 5Bristol-Myers Squibb, Lawrenceville, NJ, USA

PRM21
A21
APPLICATION OF GENERALIZED STRUCTURAL EQUATION MODEL IN A 41-YEAR COHORT STUDY OF INCIDENT AND SURVIVAL OUTCOMES OF RHEUMATOID ARTHRITIS (RA) CASES AND MATCHED NON-RA CONTROLS
Ren J, Masi AT, Aldag JC, Asche CV
University of Illinois College of Medicine at Peoria, Peoria, IL, USA

PRM22
A22
EXTENDING INFERENCES FROM RANDOMIZED PARTICIPANTS TO ALL ELIGIBLE INDIVIDUALS USING CLINICAL TRIALS NESTED WITHIN COHORTS
Robertson SE1, Dahabreh IJ1, Stuart EA2, Hernán MA3
1Brown University, Providence, RI, USA, 2John Hopkins University, Baltimore, MD, USA, 3Harvard University, Boston, MA, USA

PRM23
A23
TRANSPORTING THE RESULTS OF A CLINICAL TRIAL TO A NEW TARGET POPULATION
Dahabreh IJ, Robertson SE
Brown University, Providence, RI, USA

PRM24
A24
HOW TO CAPTURE AUTHENTIC PATIENTS' AND CAREGIVERS' EXPERIENCE WITH DISEASE AND TREATMENT: ESTABLISHING TRUST WITH THE "GATEKEEPERS" OF INFORMATION.
Stroupe A, Delbecque L
Pharmerit International, Newton, MA, USA

PRM25
A25
DEMONSTRATION OF NGRAM FREQUENCY AND CLUSTER METHOD FOR IDENTIFYING SIGNALS OF TRANSFUSION REACTIONS (TR)
Bright RA1, Bright-Ponte S2, Palmer LA2, Blok S3, Crane EC3
1Food and Drug Administration, Silver Spring, MD, USA, 2Food and Drug Administration, Rockville, MD, USA, 3Booz Allen Hamilton, Rockville, MD, USA

PRM26
A26
IMPLEMENTATION OF PIECEWISE STRUCTURAL EQUATION MODELLING (SEM) AS AN ALTERNATIVE TO TRADITIONAL SEM: A SIMULATION STUDY
Zur RM1, Aballea S2, Sherman S1
1Creativ-Ceutical, Chicago, IL, USA, 2Creativ-Ceutical, Paris, France

PRM27
A27
DEGREE OF AGREEMENT BETWEEN RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES ON DRUG EFFECTS: A SYSTEMATIC REVIEW
Acharya M1, Martin BC2
1University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA

RESEARCH ON METHODS - Cost Methods
PRM28
A28
COMPARISON OF METHODS TO ESTIMATE DISEASE-RELATED COST IN THE TRUVEN MARKETSCAN ADMINSTRATIVE CLAIMS DATABASE
Schroeder KM1, Gelwicks SC1, Schoenfeld MJ1, Naegeli A1, Heaton PC2
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Cincinnati, Cincinnati, OH, USA

PRM29
A29
INPATIENT COST OF ACUTE CARE FOR SEVERE BURN PATIENTS: VALIDATION OF ECONOMIC MODEL FOR ADULTS AND CHILDREN
Bilir SP1, Kruger E1, Kowal S2, Holmes IV H3, Hickerson W4, Foster K5, Nystrom SV6, Turley DM6, Sparks J7, Iyer N6, Quick A7
1IQVIA, San Francisco, CA, USA, 2IQVIA, Fairfax, VA, USA, 3Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA, 4University of Tennessee Health Science Center, Memphis, TN, USA, 5Arizona Burn Center, Phoenix, AZ, USA, 6US Dept. of Health and Human Services (HHS), Washington, DC, USA, 7Avita Medical, Valencia, CA, USA

PRM30
A30
THE REPORTING QUALITY OF PHARMACOECONOMIC STUDIES BEFORE AND AFTER PUBLICATION OF THE CHEERS CHECKLIST
Pandey P1, Pandey R1, Agrawal V1, Dhagale P1, Shah V1, Gupta P2
1SIRO Clinpharm Pvt Ltd, Maharashtra, India, 2All India Institute of Medical Sciences, Patna, India

PRM31
A31
A SYSTEMATIC REVIEW OF HEALTH ECONOMIC EVALUATIONS IN MEXICO
Soto Molina H1, Marquez-Cruz M2, Pardo Gutiérrez I1, Rodríguez Mendoza M2, Díaz Martínez JP3
1HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico, 2Instituto Politécnico Naciona, Ciudad de México, Mexico, 3HS Estudios Farmacoeconómicos, Mexico City, Mexico

PRM32
A32
COST-EFFECTIVENESS OF EDOXABAN COMPARED WITH DALTEPARIN FOR THE TREATMENT OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
Ma J1, Xuan S2, Lawson BO3
1University of Utah, Salt Lake City, UT, USA, 2University of Southern California, Los Angeles, CA, USA, 3HonorHealth Scottsdale Shea Medical Center, Scottsdale, AZ, USA

PRM33
A33
COST-EFFECTIVENESS ANALYSIS OF MYOSTRAIN IN SUSPECTED CORONARY ARTERY DISEASE PATIENTS
Stojanovic I, Schneider JE
Avalon Health Economics, Morristown, NJ, USA

PRM34
A34
PREDICTIVE MODEL DIRECTED INTERVENTIONS IMPROVE MEDICATION ADHERENCE PROGRAM EFFICIENCY
Lou Y, Mu Y, Rozenbaum A, Taitel MS
Walgreen Co., Deerfield, IL, USA

PRM35
A35
COST-EFFECTIVENESS ANALYSIS OF MYOSTRAIN IN THE EARLY DETECTION OF HEART FAILURE PATIENTS
Stojanovic I, Schneider JE
Avalon Health Economics, Morristown, NJ, USA

PRM36
A36
COST-EFFECTIVENESS OF PARENTERAL NUTRITION: A SYSTEMATIC LITERATURE REVIEW
Vukicevic D, Pelivanovic J, Imro M, Matveev N, Sikora A, Tatovic S, Zah V
ZRx Outcomes Research Inc., Mississauga, ON, Canada

PRM37
A37
COST EFFECTIVENESS ANALYSIS OF RISPERIDONE AND OLANZAPINE IN SCHIZOPHRENIC PATIENTS
John J1, Paul S1, E K J1, Job K1, Suresh kumar P2, Thomas RP1, MK U1
1NATIONAL COLLEGE OF PHARMACY, KMCT MEDICAL COLLEGE CAMPUS, MANASSERY, MUKKAM, calicut, India, 2KMCT Medical College, Calicut, India

RESEARCH ON METHODS - Databases & Management Methods
PRM38
A38
ACCESSING NEWLY IMPLEMENTED CLAIMS DATABASES IN SOUTHEAST-ASIA: ADVANCING HEALTH RESEARCH
Ng J1, Kiet PH2, Petcharapiruch S1
1IQVIA, Singapore, Singapore, 2Hanoi Medical University, Hanoi, Viet Nam

PRM39
A39
MERGING OF THE PEDIATRIC INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (PEDIMACS) WITH AN EXYERNAL ADMINISTRATIVE DATABASE USING INDIRECT PATIENT IDENTIFIERS TO DEVELOP A MORE COMPREHENSIVE PLATFORM FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH
Dai D1, Huang YH1, Shamszad P1, Rossano JW1, Cantor RS2, Hall M3, Kirklin JK2
1Children’s Hospital of Philadelphia, Philadelphia, PA, USA, 2University of Alabama at Birmingham, Birminghal, AL, USA, 3Children's Hospital Association, Lenexa, KS, USA

PRM40
A40
NATURAL LANGUAGE PROCESSING METHODS ENHANCE MACE IDENTIFICATION FROM ELECTRONIC HEALTH RECORDS
St. Laurent S1, Guo M1, Alfonso R1, Okoro T1, Johansen K2, Dember L3, Lindsay A1
1GSK, Collegeville, PA, USA, 2University of California, San Francisco, San Francisco, CA, USA, 3University of Pennsylvania, Philadelphia, PA, USA

PRM41
A41
TRANSITION FROM ICD-9-CM TO ICD-10-CM DIAGNOSIS CODING SYSTEM IN THE UNITED STATES – FINDINGS FROM HEMOPHILIA A
Yang E, Patel AM, Whiteley J, Yeh W
Genentech, Inc., South San Francisco, CA, USA

PRM42
A42
RESEARCH ON ISPOR MEETINGS/CONGRESSES/CONFERENCES: A BIBLIOMETRIC ANALYSIS FROM 2002 TO 2017
Bendezu-Quispe G1, Díaz-Seijas D2, Azañedo D3, Hernández-Vásquez A4
1Universidad de San Martín de Porras, Lima, Peru, 2Instituto Nacional Cardiovascular-INCOR- EsSalud, Lima, Peru, 3Universidad Católica los Ángeles de Chimbote (ULADECH-Católica), Chimbote, Peru, 4Universidad Privada del Norte, Lima, Peru

PRM43
A43
NEW STRUCTURED SEARCH METHOD THAT ALLOWS IDENTIFY AND MAP POTENTIAL PATIENTS WITH CYSTIC FIBROSIS NOT YET DIAGNOSED.
de Paula E, Rosito F, Vaz P, Vaz G, Melo T
Heads in Health, São Paulo, Brazil

PRM44
A44
EVALUATION OF ELECTRONIC HEALTH RECORD DATA QUALITY TO ASSESS THE CLINICAL INDICES OF ANEMIA IN DIALYSIS PATIENTS
St. Laurent S1, Alfonso R1, Okoro T1, Johansen K2, Dember L3, Sikirica V1, Lindsay A1
1GSK, Collegeville, PA, USA, 2University of California, San Francisco, San Francisco, CA, USA, 3University of Pennsylvania, Philadelphia, PA, USA

PRM45
A45
DIFFICULTY OF MEASURING DOSE RESPONSE DUE TO UNRELIABILITY OF DAYS SUPPLY IN ADMINISTRATIVE CLAIMS DATA
Zambelli-Weiner A, Via C, Yuen M, Weiner D, Bauserman R
Translational Technologies International, Hampstead, MD, USA

PRM46
A46
VALIDATION OF A CLAIMS-BASED ALGORITHM FOR IDENTIFICATION OF PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE US
Korytowsky B1, Radtchenko J2, Abraham P1, Klinefelter P2, Shaw JW1, Feinberg B2
1Bristol-Myers Squibb, Lawrenceville, NJ, USA, 2Cardinal Health, Dublin, OH, USA

PRM47
A47
NAVIGATING REAL WORLD EVIDENCE IN ONCOLOGY – WHERE TO GO AND WHY
Macaulay R1, Sharma A2, Prakash V2, Medin E3, Anell B3
1PAREXEL International, London, UK, 2PAREXEL International, Chandigarh, India, 3PAREXEL International, Stockholm, Sweden

PRM48
A48
STUDY ON THE IMMUNE MECHANISM OF DENDRITIC CELLS AGAINST MEASLES VIRUS BY BIOINFORMATICS
Jia L, Zhang R
Shaanxi University of Chinese Medicine, Xi'an, China

PRM49
A49
A REVIEW OF DEFINITION OF SMOKING STATUS WHEN USING ELECTRONIC MEDICAL/HEALTH RECORDS AND CLAIMS DATABASES IN STUDIES
Shao Y, Shi L
Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

PRM50
A50
USING AGGREGATE DATA TO PROXY INDIVIDUAL-LEVEL CHARACTERISTICS IN HEALTH SERVICES RESEARCH: 9-DIGIT ZIPCODE VS. CENSUS BLOCK GROUP
Kilgore K1, McClellan M1, Teigland C1, Pulungan Z2
1Avalere Health - An Inovalon Company, Bowie, MD, USA, 2Avalere Health - An Inovalon Company, Washington, DC, USA

PRM51
B1
ASSOCIATION RULE MINING TO IDENTIFY FREQUENT CONCOMITANT USE OF PRESCRIBED MEDICATIONS IN THE POPULATION
Olaisen RH, Stange KC, Schiltz NK
Case Western Reserve University, Cleveland, OH, USA

PRM52
B2
LEVERAGING CLINICAL FIELDS FROM A US EMR DATABASE TO IDENTIFY AND CHARACTERIZE LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) IN REAL WORLD PRACTICE SETTINGS
Aguilar D, Yuan G, Wade RL, Lu J, Lichtenstein M
IQVIA, Plymouth Meeting, PA, USA

PRM53
B3
FACTORS ASSOCIATED WITH DATA COLLECTION DURATION AND PARTICIPATION RATES IN RETROSPECTIVE NONINTERVENTIONAL MEDICAL RECORD REVIEW STUDIES
Levine CA1, Kurosky S1, Ansquer V2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AplusA Real World, LYON, France

PRM54
WITHDRAWN

RESEARCH ON METHODS - Modeling Methods
PRM55
WITHDRAWN

PRM56
B4
REHOSPITALIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: IMPORTANT RISK FACTORS AND RISK PREDICTION MODEL USING CLARIFICATION RANDOM FOREST
Nguyen T1, Carlson AM2, Heins Nesvold J3
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, 3American Lung Association of the Upper Midwest, St. Paul, MN, USA

PRM57
B5
A PREDICTIVE MODELING APPROACH THAT ACCURATELY IDENTIFIES MEMBERS WITH THE LIKELIHOOD OF HAVING A FUTURE COSTLY EVENT
Holloway J, Guh S, Washington V, Cantrell D, Chaisson J, Tisdale K, Bergeron T, Liu M, Nigam S
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

PRM58
B6
THE USE OF HISTORICAL TRIAL DATA TO INFORM EXTRAPOLATIONS OF IMMATURE SURVIVAL DATA WITHIN A BAYESIAN FRAMEWORK IN COMPARISON TO STANDARD APPROACHES
Soikkeli F1, Hashim M1, Postma M2, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2University of Groningen, Groningen, The Netherlands

PRM59
B7
A MODIFIED PARAMETRIC APPROACH TO MODEL LONG-TERM SURVIVAL OF POTENTIALLY CURATIVE THERAPIES: IMPLICATIONS FOR THE COST-EFFECTIVENESS OF CAR-T THERAPIES
Whittington MD1, McQueen RB1, Kim C1, Patidar M1, Ollendorf DA2, Kumar VM2, Chapman RH2, Tice JA3, Campbell JD1
1University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Institute for Clinical and Economic Review, Boston, MA, USA, 3UCSF School of Medicine, San Francisco, CA, USA

PRM60
B8
ASSESSING MULTI-CRITERIA DECISION ANALYSIS (MCDA) ATTRIBUTE WEIGHTS USING AN INTERACTIVE DATA CAPTURE TOOL
Schey C1, Connolly M2, Volovyk A3, Topachevskyi O4, Kotsopoulos N5
1University of Groningen, Groningen, The Netherlands, 2Global Market Access Solutions, Saint-Prex, Switzerland, 3Digital Health Outcomes, Kiev, Ukraine, 4Digital Health Outcomes, Brussels, Belgium, 5Health Policy Institute, Athens, Greece

PRM61
B9
A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY: NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) AS AN ILLUSTRATIVE EXAMPLE
Mullins CD1, Le H2, Lawson J2, Pan F2
1University of Maryland, Baltimore, MD, USA, 2Janssen Research and Development, Raritan, NJ, USA

PRM62
B10
REVIEW AND VALIDATION OF CARDIOVASCULAR RISK PREDICTION MODELS IN EAST ASIAN POPULATIONS
Foos V1, McEwan P2, Lamotte M1
1QuintilesIMS, Zaventem, Belgium, 2Health Economics & Outcomes Research Ltd, Cardiff, UK

PRM63
B11
THE PAST, PRESENT AND FUTURE OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) APPLIED IN MEDICAL FIELD
Wu M1, Hsu JC2, Tseng Y2
1National University of Tainan, Tainan, Taiwan, 2National Cheng Kung University, College of Medicine, Tainan, Taiwan

PRM64
B12
RESULTS OF A TARGETED LITERATURE REVIEW ON THE COST-EFFECTIVENESS MODELS DEVELOPED FOR RETINOPATHY OF PREMATURITY
Nemeth B1, Zelei T1, Szeles G1, Jakab I1, Schmidt F2, Kalo Z1
1Syreon Research Institute, Budapest, Hungary, 2Orphan Europe, Puteaux, France

PRM65
B13
PREDICTIVE MODEL FOR EARLIER DIAGNOSIS OF DEMENTIA USING ADMINISTRATIVE CLAIMS
Albrecht J1, Hanna ML2, Kim D2, Perfetto EM2
1University of Maryland, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM66
B14
SYNTHETIC SAMPLE GENERATION REPRESENTING THE ENGLISH POPULATION USING SPEARMAN RANK CORRELATION AND CHOMSKY DECOMPOSITION
Martin C, Springate CE
Crystallise, East Tilbury, UK

PRM67
B15
CREATING A FLEXIBLE CONTINUOUS PROCEDURE DISTRIBUTION MODEL BASED ON PRE-TEST RISK LEVEL FOR LUNG CANCER IN PATIENTS WITH INCIDENTALLY DETECTED PULMONARY NODULES
Piscitello A1, Rinde H2, Silvestri GA3, Tanner NT3, Soneji SS4
1EmpiriQA, Long Grove, IL, USA, 2BioBridge Strategies, San Diego, CA, USA, 3Medical University of South Carolina, Charleston, SC, USA, 4Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA

PRM68
B16
UTILIZING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TO CREATE A BETTER MEMBER EXPERIENCE: BLUE CROSS BLUE SHIELD OF LOUISIANA (BCBSLA) INNOVATION IN ACTION
Holloway J, Nigam S
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

PRM69
B17
ESTIMATING THE GLOBAL DIAGNOSED PREVALENCE OF CROHN'S DISEASE 2017-2027
Giegerich E1, Ayodele O2, John A2, Hughes M2, van der Pluijm W2, Gezmu T2
1Decision Resources Group, Parsippany, NJ, USA, 2Decision Resources Group, Burlington, MA, USA

PRM70
B18
ASSESSING DRUG PRICE CHANGES OVER 1 YEAR AND THEIR INFLUENCE ON BUDGET IMPACT
Mezzio D, Brown D
Xcenda, LLC, Palm Harbor, FL, USA

PRM71
B19
USE OF THE WEIBULL PROPORTIONAL HAZARDS MODEL TO ESTIMATE OS AND PFS IN 9 BLOOD CANCER INDICATIONS: VALIDATION AND VIOLATION
Nicoloso D, Zhang C, Kratochvil D, Snedecor SJ
Pharmerit International, Bethesda, MD, USA

PRM72
B20
PREDICTING ALZHEIMER DIESEASE USING LONGITUDINAL MAGNETIC RESONANCE IMAGING DATA
Wang B1, Guo Z2, Yu B3
1Ivy Analytics LLC, Garnet Valley, PA, USA, 2Shuttack St Mary's School, Faribault, MN, USA, 3Zhejiang Jinhua No1 High School, Jinhua, China

PRM73
B21
POPULATION MODELS SUPPPORTING DECISION MAKING ON A POLICY LEVEL – A SYSTEMATIC REVIEW
Jahn B1, Conrads-Frank A1, Sroczynski G1, Rochau U1, Zauner G2, Gyimesi M3, Bundo M1, Thokala P4, Endel G5, Popper N6, Siebert U7
1Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 2dwh GmbH, simulation services / DEXHELPP (Decision Support for Health Policy and Planning), Vienna, Austria, 3Austrian Public Health Institute, Vienna, Austria, 4The University of Sheffield, Sheffield, UK, 5Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 6dwh GmbH, simulation services / Technical University, Institute for Analysis and Scientific Computing, Vienna, Austria, 7UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health. Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA

PRM74
B22
RISK-STRATIFICATION METHOD FOR IDENTIFYING PATIENTS FOR CARE COORDINATION – REAL-WORLD EXPERIENCE IN THE HEALTH PLAN, BRAZIL
Reis Neto JP1, Busch JM2
1Federal University of Maranhao, Rio de Janeiro, Brazil, 2Souza Marques University, Rio de Janeiro, Brazil

PRM75
B23
CONVERSION OF HYPOGLYCEMIA UTILITY DECREMENTS FROM CATEGORICAL UNITS REFLECTING EVENT HISTORY INTO EVENT SPECIFIC DISUTILITY SCORES APPLICABLE TO DIABETES DECISION MODELS
Foos V1, McEwan P2
1QuintilesIMS, Zaventem, Belgium, 2Health Economics & Outcomes Research Ltd, Cardiff, UK

PRM76
B24
USING STRUCTURAL EQUATION MODEL TO EVALUATE PATIENT SATISFACTION TO A PHARMACIST-LED MEDICATION EDUCATION SERVICE FOR ACUTE MYOCARDIAL INFARCTION
Chen C1, Chen H2, Chou TR3
1Taipei Municipal Wanfang Hospital (Managed by Taipei Medical University), Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Ming Chuan University, Taoyuan, Taiwan

PRM77
B25
AN OPEN-SOURCE TOOLKIT FOR DEVELOPING FLEXIBLE EVIDENCE-BASED DECISION AND SIMULATION MODELS FOR VALUE ASSESSMENT IN ONCOLOGY WITH R
Incerti D, Jansen JP
Innovation and Value Initiative; Precision Health Economics, Los Angeles, CA, USA

PRM78
B26
RECURSIVELY IMPUTED SURVIVAL TREES FOR EXTRAPOLATING SURVIVAL BEYOND CLINICAL TRIAL FOLLOW UP: A SIMULATION STUDY
Beyhaghi H, Hassmiller Lich K, Cui Y, Kosorok MR
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PRM79
B27
1. INDIRECT TREATMENT COMPARISON OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE FOR RELAPSED AND REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA USING TIME-VARYING HAZARD RATIOS
Wu E1, Keeping S2, Chan K2, Mojebi A2, Balakumaran A1
1Merck, North Wales, PA, USA, 2Precision Xtract, Vancouver, BC, Canada

PRM80
B28
A NOVEL MODELLING APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INTERVENTIONS
Asukai Y1, Gunsoy NB2, Koblbauer I3, Pascoe K1, Williams J3, Vetrini D3, Kay G3, Mealing S3, Fenwick E3
1GSK, Brentford, UK, 2Value Evidence and Outcomes, GSK, Uxbridge, Middlesex, UK, 3ICON Health Economics, ICON plc, Abingdon, UK

PRM81
B29
A VALIDATION OF PIECEWISE STRUCTURAL EQUATION MODELLING (SEM) COMPARED TO TRADITIONAL STRUCTURAL EQUATION MODELLING: A SIMULATION STUDY
Zur RM1, Aballea S2, Sherman S1
1Creativ-Ceutical, Chicago, IL, USA, 2Creativ-Ceutical, Paris, France

PRM82
B30
MODEL-BASED NETWORK META-ANALYSIS FOR TIME COURSE RELATIONSHIPS: A UNION OF TWO METHODOLOGIES
Pedder H1, Boucher M2, Dias S1, Bennetts M2, Welton NJ1
1University of Bristol, Bristol, UK, 2Pfizer Limited, Sandwich, UK

PRM83
B31
WITHDRAWN

PRM84
B32
SMALL CHANGES, BIG DIFFERENCES? COHORT VARIATION BY PARAMETER SPECIFICATIONS IN CLAIMS-BASED DRUG USE EVALUATIONS
Huang T1, Hou L1, Shockro L1, Pestine E1, Nguyen M2, Maro J1, Izem R2
1Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA, 2U.S. Food and Drug Administration, Silver Spring, MD, USA

PRM85
B33
A REVIEW OF NICE TECHNOLOGY APPRAISALS IN ONCOLOGY USING SINGLE ARM TRIALS (SAT) EVIDENCE
Alexiou D1, Chatzitheofilou I2, Pi Blanque A2
1AbbVie, Maidenhead, UK, 2IQVIA, London, UK

RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM86
B34
AN INVESTIGATION OF ISSUES IN THE TRANSLATION AND COMPREHENSION OF THE CONCEPT OF DISEASE ACTIVITY IN PATIENT REPORTED OUTCOMES (PRO) MEASURES
Poepsel T1, Brandt B2, Yohe Moore ES1, McCullough E2, McKown S2
1RWS Life Sciences, Chicago, IL, USA, 2RWS Life Sciences, East Hartford, CT, USA

PRM87
B35
PSYCHOMETRIC VALIDATION OF THE 1-MONTH RECALL UTERINE FIBROID SYMPTOM AND HEALTH-RELATED QUALITY-OF-LIFE QUESTIONNAIRE
Coyne KS1, Harrington A2, Currie BM1, Chen J1, Gillard P2, Spies JB3
1Evidera, Bethesda, MD, USA, 2Allergan plc, Irvine, CA, USA, 3MedStar Georgetown University Hospital, Washington, DC, USA

PRM88
B36
ESTIMATING PATIENT UTILITY IN MIGRAINE: LONGITUDINAL ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA
Di Tanna GL1, Porter JK1, Lipton RB2, Hatswell AJ3, Sapra S4, Villa G1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of Medicine, Bronx, NY, USA, 3Delta Hat Limited, Nottingham, UK, 4Amgen Inc, Thousand Oaks, CA, USA

PRM89
B37
REVIEW OF FREQUENTLY IMPLEMENTED PATIENT REPORTED OUTCOMES IN CURRENT PROSTATE CANCER CLINICAL TRIALS
Grimes R, Grant L, Kaur S, Brookes B, Bennett B
Adelphi Values Ltd, Bollington, Cheshire, UK

PRM90
B38
PSYCHOMETRIC EVALUATION OF QUESTIONNAIRES ASSESSING INJECTION REGIMEN BURDEN IN GROWTH HORMONE DEFICIENT (GHD) ADULTS AND CHILDREN TREATED WITH GROWTH HORMONE
Turner-Bowker DM1, Yaworsky A1, Palladino A2, Pleil A3, Shields AL1, Kelly M1, Lamoureux RE1, Love E1, Morrissey L1, Loftus J4
1Adelphi Values, Boston, MA, USA, 2Pfizer, Inc., Collegeville, PA, USA, 3Pfizer Inc, San Diego, CA, USA, 4Pfizer Ltd, Tadworth, UK

PRM91
B39
DEVELOPMENT AND PSYCHOMETRIC TESTING OF THE ADHERENCE PROMOTION ACTIVITIES SCALE FOR PHARMACIST-INITIATED HIV PATIENT CARE IN AMBULATORY SETTINGS
Kibicho J1, Owczarzak J2, Ndakuya F1
1University of Wisconsin-Milwaukee, Milwaukee, WI, USA, 2John Hopkins University, Baltimore, MD, USA

PRM92
B40
EVALUATION OF MODIFIED ITEM CHARACTERISTICS ON ITEM COMPREHENSION AND PSYCHOMETRIC PERFORMANCE
Turner-Bowker DM1, DeRosa M1, Bjorner JB2
1Adelphi Values, Boston, MA, USA, 2Optum Patient Insights, Johnston, RI, USA

PRM93
B41
WHAT IS THE RELATIONSHIP BETWEEN THE EQ-5D-5L AND ASCOT? EVIDENCE FROM AN AUSTRALIAN SAMPLE
Mulhern B1, Norman R2, Street D1, Viney R3, Bird E1
1University of Technology Sydney, Sydney, Australia, 2Curtin University, Perth, Australia, 3University of Technology, Sydney, Sydney, Australia

PRM94
B42
QUALITY OF LIFE OF ADULTS WITH A HISTORY OF JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW
Grazziotin Lago L1, Currie G1, Kip MM2, IJzerman MJ3, Twilt M4, Marshall DA4
1Univeristy of Calgary, Calgary, AB, Canada, 2Linköping University, Linköping, Sweden, 3University of Twente, Enschede, The Netherlands, 4University of Calgary, Calgary, AB, Canada

PRM95
B43
ASSESSING CHRONIC DISEASE MEDICATION ADHERENCE
Nobles BM1, Erickson S2, Marshall V2
1University of Michigan, Ann Arbor, MI, USA, 2UNIVERSITY OF MICHIGAN, ANN ARBOR, MI, USA

PRM96
B44
METHODS FOR REPORTING THE PATIENT-REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) DATA IN CANCER CLINICAL TRIALS
Zhou X, Eid D, Gnanasakthy A
RTI Health Solutions, Research Triangle Park, NC, USA

PRM97
B45
CRITICAL APPRAISAL OF PSYCHOMETRIC METHODS USED IN VALIDATION OF PATIENT-REPORTED OUTCOMES MEASURES
Rabenda V, Leclercq V, Reginster J, Bruyère O
University of Liège, Liège, Belgium

PRM98
B46
VALUATION OF PREFERENCE-BASED MEASURES: CAN EXISTING PREFERENCE DATA BE USED TO SELECT A SMALLER SAMPLE OF HEALTH STATES?
Kharroubi S
Department of Nutrition and Food Sciences, Beirut, Lebanon

PRM99
C1
REVIEW OF TERMINOLOGY OF MEASUREMENT PROPERTIES FOR PATIENT-REPORTED OUTCOME MEASURES
Rabenda V, Leclercq V, Reginster J, Bruyère O
University of Liège, Liège, Belgium

PRM100
C2
COMPARING THE EQ-5D-3L AND EQ-5D-5L IN A COHORT OF CANCER PATIENTS
Lorgelly P1, Cubi-Molla P1, Pennington MW2, Norman R3
1Office of Health Economics, London, UK, 2King's College London, London, UK, 3Curtin University, Perth, Australia

PRM101
C3
LINGUISTIC VALIDATION OF THE ENDOMETRIOSIS TREATMENT SATISFACTION QUESTIONNAIRE (ETSQ) IN 3 LANGUAGES FOR ENDOMETRIOSIS PATIENTS
Brandt B1, Soliman AM2, Poepsel T3, Yohe Moore ES3, McCullough E1, McKown S1
1RWS Life Sciences, East Hartford, CT, USA, 2AbbVie, North Chicago, IL, USA, 3RWS Life Sciences, Chicago, IL, USA

PRM102
C4
DEVELOPMENT AND PRELIMINARY ASSESSMENT OF THE ENVIRONMENT-BASED QUALITY OF LIFE (EBQOL) INSTRUMENT
Wu H1, Ran X1, Zhang T1, Cai Y1, Xiao Y1, Yang X1, Xue W1, Zhang M2
1Guizhou Medical University, Guiyang, China, 2Guizhou Provincial People's Hospital, Guiyang, China

PRM103
C5
DEVELOPMENT AND INITIAL VALIDATION OF THE PERCEPTIONS, ATTITUDES AND CHALLENGES OF PHYSICIANS TOWARDS DEPRESCRIBING (PACPD-12) QUESTIONNAIRE
Bhat D1, G R S2, K R3, Singh Ks4
1M. S. Ramaiah College of Pharmacy, Bangalore, India, 2Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bangalore, India, 3M S Ramaiah Medical College, Bangalore, India, 4Faculty of Pharmacy, M. S . Ramaiah University of Applied Sciences, Bangalore, India

PRM104
C6
CHALLENGES IN TRANSLATING THE SHEEHAN SUICIDALITY TRACKING SCALE (UPDATED ADULT VERSION)
Vasarri S1, Sheehan DV2, Anfray C3, Acquadro C4
1Mapi, An ICON plc Company, Yardley, PA, USA, 2University of South Florida College of Medicine, Tampa, FL, USA, 3Mapi Research Trust, Lyon, France, 4Mapi, An ICON plc Company, Lyon, France

PRM105
C7
SELF-ASSESSED LIFE EXPECTANCY AMONG THE ELDERLY IN DEVELOPING COUNTRIES: EVIDENCE FROM CÔTE D’IVOIRE
Moussa RK1, Diaby V2
1Ecole Nationale Superieure de Statistique et d'Economie Appliquee, Abidjan, Côte d'Ivoire, 2University of Florida, Gainesville, FL, USA

PRM106
C8
CALCULATING RASCH-BASED PERSON PARAMETERS FOR INDIVIDUAL ITEMS
Cole JC1, Goyal A2, Cheng R1, Moulton MH3
1ZS Associates, Thousand Oaks, CA, USA, 2ZS Associates, Haryana, India, 3Educational Data Systems, Morgan Hill, CA, USA

PRM107
C9
MISSING DATA IN PATIENT-REPORTED OUTCOMES: REGULATORY, STATISTICAL, AND OPERATIONAL PERSPECTIVES
Chan EK1, Jamieson C2, Metin H3, Hudgens S4
1Janssen Global Services, LLC, Raritan, NJ, USA, 2Janssen Global Services, LLC, Fremont, CA, USA, 3Janssen-Cilag GmbH, North Rhine-Westphalia, Germany, 4Clinical Outcomes Solutions, Tucson, AZ, USA

RESEARCH ON METHODS - Statistical Methods
PRM108
C10
AN EXACT METHOD FOR ESTIMATING STANDARD ERRORS FROM ZERO-INFLATED GAMMA DISTRIBUTIONS FOR HEALTHCARE COST DATA
Parks DC1, Ferrante SA2
1GSK, Phoenixville, PA, USA, 2GSK, Collegeville, PA, USA

PRM109
C11
A COMPARISON OF PATIENT LEVEL DATA (IPD) REGRESSION TECHNIQUES IN ADJUSTING FOR CROSS TRIAL DIFFERENCES IN AN INDIRECT TREATMENT COMPARISON (ITC): A WORKED EXAMPLE OF SIMULATED TREATMENT COMPARISON (STC) VS BAYESIAN IPD REGRESSION
Shukla P, Sharma A, Siddiqui MK
PAREXEL International, Chandigarh, India

PRM110
C12
HUMANISTIC AND ECONOMIC BURDEN ASSOCIATED WITH ANXIETY AND DEPRESSION AMONG ADULTS WITH DIABETES AND HYPERTENSION
Wallace K, Misra R, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PRM111
C13
THE IMPACT OF CLUSTER SELECTION METHODS IN TWO-STAGE BOOTSTRAPPING TO ASSESS UNCERTAINTY IN HEALTH ECONOMIC OUTCOMES IN CLUSTER RANDOMIZED CONTROLLED TRIALS
Kip MM1, Berghuis AS1, Nijsten MW2, IJzerman MJ1, Koffijberg H1
1University of Twente, Enschede, The Netherlands, 2University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PRM112
C14
IS THERE A CONSENSUS REGARDING CLINICALLY RELEVANT NON-INFERIORITY MARGINS USED FOR KEY ONCOLOGY ENDPOINTS IN NON-INFERIORITY ONCOLOGY TRIALS?
Hashim M1, He J2, Hu P3, Soikkeli F1, Gebregergish S1, Heeg B1, Lam A2
1Ingress Health, Rotterdam, The Netherlands, 2Janssen Global Services, LLC, Raritan, NJ, USA, 3Janssen R&D, Raritan, NJ, USA

PRM113
C15
SOCIOECONOMIC AND PSICOSOCIAL FACTOR RELATED TO THE PREVALENCE OF DEPRESSION IN BRAZIL
Balbinotto Neto G1, Silveira E2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 2UFRGS - IATS, PORTO ALEGRE, Brazil

PRM114
C16
WAGES AND CARDIOVASCULAR PROBLEMS: THE BRAZILIAN CASE
Balbinotto G, Oliveira V, Silveira E
UFRGS - IATS, PORTO ALEGRE, Brazil

PRM115
C17
A WRINKLE IN TIME: WHEN SURVIVAL ESTIMATES CHANGE OVER THE OBSERVATION PERIOD
Smith BN
ICON Clinical Research, North Wales, PA, USA

PRM116
C18
DO MODELS WITH BETTER GOODNESS OF FIT ENSURE LESS BIASED TREATMENT EFFECT ESTIMATES?
Li P, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA

RESEARCH ON METHODS - Study Design
PRM117
C19
THE APPLICATION OF ELECTRONIC MEDICAL RECORDS (EMRS) AS A VIRTUAL COMPARATOR ARM IN A LUNG CANCER CLINICAL TRIAL
Patel KA1, Ouwens MJ2, Shire N3, Khosla S4
1AstraZeneca Ltd., Cambridge, UK, 2Astrazeneca, Molndal, Sweden, 3AstraZeneca, Gaithersburg, MD, USA, 4Astrazeneca, Cambridge, UK

PRM118
WITHDRAWN

PRM119
C20
A SYSTEMATIC LITERATURE REVIEW OF METHODOLOGY TO DETERMINE TREATMENT PERSISTENCE IN INFLAMMATION AND IMMUNOLOGY OBSERVATIONAL DATABASE STUDIES
Amari DT, Corvino FA, Safran NZ, Zivkovic M
Genesis Research, Hoboken, NJ, USA

PRM120
C21
WHAT’S THE BURDEN OF BURDEN OF ILLNESS REVIEWS?
Betts MB1, Nambiar S2, Khankhel Z1, Nejati M1, Lewis J1, Cichewicz A1, Snook K1, Martin AL1
1Evidera, Waltham, MA, USA, 2MCPHS University, Boston, MA, USA

PRM121
C22
ASSESSING CELLULITE SEVERITY: METHOD FOR ASSESSING RELIABILITY OF A NEW CLINICIAN-REPORTED AND A NEW PATIENT-REPORTED PHOTONUMERIC SCALE
Kirby MT1, McLane MP1, Lenderking WR2, Bender R2, Chen J2, Hurley D1, Knoble N2, Liu G1, Davidson JA1
1Endo Pharmaceuticals Inc., Malvern, PA, USA, 2Evidera, Bethesda, MD, USA

PRM122
C23
UTILIZING REAL-WORLD DATA TO INFORM A CONFIRMATORY BASKET TRIAL DESIGN: STUDYING USE OF RITUXIMAB IN AUTOIMMUNE DISEASES
Guinn D1, Ren Y1, Wilhelm EE1, Deeb H2, Brooks IM2, Korostyshevskiy VR1, Madhavan S1, Beckman RA1
1Georgetown University, Washington, DC, USA, 2MedStar Health Research Institute, Hyattsville, MD, USA

PRM123
C24
ASSESSING QUALITY IN QUALITATIVE RESEARCH TO UNDERSTAND DISEASE BURDEN; WHAT TOOLS ARE AVAILABLE?
Aldhouse NV, Kitchen H
DRG Abacus, Manchester, UK

PRM124
C25
HOW IS REAL WORLD DATA CURRENTLY USED BY INDUSTRY PROFESSIONALS?
Keetley M, Pulfer A, Bottomley CJ
pH Associates (an Open Health company), Marlow, UK

PRM125
C26
A METHOD TO USE ADMINISTRATIVE CLAIMS TO CATEGORIZE DEMENTIA CASES BY SUBTYPE
Hanna ML1, Kim D1, Albrecht J2, Perfetto EM1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MA, USA

PRM126
C27
RISK OF ABNORMAL LIVER FUNCTION IN AUTOIMMUNE PATIENTS RECEIVING ANTI-TNF-Α AGENTS VARIES BETWEEN THOSE WITH DIFFERENT HEPATITIS B VIRUS INFECTION STATUS
Chiu Y
Changhua Christian Hospital, Changhua City, Taiwan

PRM127
C28
A COMPARISON OF AMSTAR AND ROBIS TOOLS FOR METHODOLOGICAL QUALITY ASSESSMENT OF SYSTEMATIC REVIEWS OF ALZHEIMER’S DISEASE
Inuganti B1, Inuganti A1, Vsn M1, Hyderboini RK1, Chakrawarthy M1, Chidirala SR1, Nadimpally J1, Dang A2
1MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India, 2MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, MA, India

PRM128
C29
ANALYZING PRESCRIPTION DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS: A CASE STUDY IN NARCOLEPSY
Ling T, Tzellos S
IQVIA, London, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.